Triple negative breast cancer: Clinicopathological characteristics and treatment strategies

Breast Cancer

Volumn 16, Issue 4, 2009, Pages 252-253

  Akiyama, Futoshi ^a   Iwase, Hirotaka ^b  

^a CANCER INSTITUTE   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Basal like tumor; Triple negative breast cancer

Indexed keywords

BRCA1 PROTEIN; CETUXIMAB; CYTOKERATIN 14; CYTOKERATIN 5; CYTOKERATIN 6; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; ESTROGEN RECEPTOR; IMATINIB; PROGESTERONE RECEPTOR; SUNITINIB;

BREAST CANCER; CANCER THERAPY; CLINICAL FEATURE; CONFERENCE PAPER; DNA MICROARRAY; HUMAN; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROGNOSIS;

BREAST NEOPLASMS; FEMALE; HUMANS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 70349687454     PISSN: 13406868     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12282-009-0140-x     Document Type: Conference Paper

References (3)

1. H Iwase Y Yamamoto 2008 Biological characteristics of triple negative breast cancer Jpn J Breast Cancer 23 2 75 80
2. S Kobayashi 2008 Basal-like subtype of breast cancer: a review of its unique characteristics and their clinical significance. javascript:AL-get(this, 'jour', 'Breast Cancer.') Breast Cancer 15 2 153 158 18311481 10.1007/s12282-008-0034-3
3. N Honma R Horii T Iwase S Saji M Younes K Takubo, et al. 2008 Clinical importance of estrogen receptor-b evaluation in breast cancer patients treated with adjuvant tamoxifen therapy J Clin Oncol 26 3727 3734 18669459 10.1200/JCO.2007.14.2968